Literature DB >> 20005488

Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene.

Marina Núñez1, Anita M Saran, Barry I Freedman.   

Abstract

HIV-associated nephropathy (HIVAN) is a leading cause of ESRD in African Americans. The HIV-1 virus infects podocytes, cells integral to formation of the glomerular filtration barrier, often leading to focal segmental glomerulosclerosis. HIVAN is typically a complication of late-stage HIV infection, associated with low CD4 cell counts and elevated serum HIV RNA levels. Highly active antiretroviral therapy is partially protective and has altered the natural history of HIV-associated kidney disease. Nonetheless, HIVAN remains an important public health concern among HIV-infected African Americans. Although polymorphisms in the MYH9 gene on chromosome 22 are strongly associated with HIVAN, as well as with idiopathic focal segmental glomerulosclerosis and global glomerulosclerosis (historically labeled "hypertensive nephrosclerosis"), the majority of HIV-infected patients who are genetically at risk from MYH9 do not appear to develop severe kidney disease. Therefore, we postulate that additional environmental exposures and/or inherited factors are necessary to initiate human HIVAN. Gene-environment interactions have also been proposed as necessary for the initiation of HIVAN in murine models. It is important that these novel risk factors be identified because prevention of environmental exposures and targeting of additional gene products may reduce the risk for HIVAN, even among those harboring 2 risk alleles in MYH9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20005488      PMCID: PMC2814053          DOI: 10.1053/j.ackd.2009.08.002

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  57 in total

Review 1.  Renal biopsy is necessary for the diagnosis of HIV-associated renal diseases.

Authors:  Scott D Cohen; Paul L Kimmel
Journal:  Nat Clin Pract Nephrol       Date:  2008-11-18

2.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

Review 3.  Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts).

Authors:  V D D'Agati
Journal:  Kidney Int       Date:  2007-11-07       Impact factor: 10.612

4.  End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004.

Authors:  Gregory M Lucas; Shruti H Mehta; Mohamed G Atta; Gregory D Kirk; Noya Galai; David Vlahov; Richard D Moore
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

5.  HIV-1 Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein.

Authors:  Ting-Chi Lu; John Cijiang He; Zhao-Hui Wang; Xiaobei Feng; Tomoko Fukumi-Tominaga; Nan Chen; Jin Xu; Ravi Iyengar; Paul E Klotman
Journal:  J Biol Chem       Date:  2008-01-30       Impact factor: 5.157

6.  Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races.

Authors:  Gregory M Lucas; Bryan Lau; Mohamed G Atta; Derek M Fine; Jeanne Keruly; Richard D Moore
Journal:  J Infect Dis       Date:  2008-06-01       Impact factor: 5.226

7.  Predictors of renal outcome in HIV-associated nephropathy.

Authors:  Frank A Post; Lucy J Campbell; Lisa Hamzah; Lisa Collins; Rachael Jones; Rizwan Siwani; Leann Johnson; Martin Fisher; Stephen G Holt; Sanjay Bhagani; Andrew H Frankel; Edmund Wilkins; Jonathan G Ainsworth; Nick Larbalestier; Derek C Macallan; Debasish Banerjee; Guy Baily; Raj C Thuraisingham; Paul Donohoe; Bruce M Hendry; Rachel M Hilton; Simon G Edwards; Robert Hangartner; Alexander J Howie; John O Connolly; Philippa J Easterbrook
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

8.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans.

Authors:  W H Linda Kao; Michael J Klag; Lucy A Meoni; David Reich; Yvette Berthier-Schaad; Man Li; Josef Coresh; Nick Patterson; Arti Tandon; Neil R Powe; Nancy E Fink; John H Sadler; Matthew R Weir; Hanna E Abboud; Sharon G Adler; Jasmin Divers; Sudha K Iyengar; Barry I Freedman; Paul L Kimmel; William C Knowler; Orly F Kohn; Kristopher Kramp; David J Leehey; Susanne B Nicholas; Madeleine V Pahl; Jeffrey R Schelling; John R Sedor; Denyse Thornley-Brown; Cheryl A Winkler; Michael W Smith; Rulan S Parekh
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

9.  Observations on a cohort of HIV-infected patients undergoing native renal biopsy.

Authors:  Adam R Berliner; Derek M Fine; Gregory M Lucas; M Hafizur Rahman; Lorraine C Racusen; Paul J Scheel; Mohamed G Atta
Journal:  Am J Nephrol       Date:  2008-01-04       Impact factor: 3.754

10.  Racial differences in end-stage renal disease rates in HIV infection versus diabetes.

Authors:  Andy I Choi; Rudolph A Rodriguez; Peter Bacchetti; Daniel Bertenthal; Paul A Volberding; Ann M O'Hare
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

View more
  3 in total

Review 1.  Potential effects of MYH9-associated nephropathy on dialysis and kidney transplant outcomes.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Semin Dial       Date:  2010-05-10       Impact factor: 3.455

2.  Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.

Authors:  Duncan B Johnstone; Jidong Zhang; Britta George; Catherine Léon; Christian Gachet; Hetty Wong; Rulan Parekh; Lawrence B Holzman
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

3.  Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.

Authors:  Barry I Freedman; Carl D Langefeld; Lingyi Lu; Jasmin Divers; Mary E Comeau; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Randall C Johnson; Nicholette D Palmer; Pamela J Hicks; Meredith A Bostrom; Jessica N Cooke; Caitrin W McDonough; Donald W Bowden
Journal:  PLoS Genet       Date:  2011-06-16       Impact factor: 5.917

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.